title: The effect of pegaptanib (Macugen(®) ) injection on retinal and retrobulbar blood flow in retinal Ischaemic diseases.
authors: Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA.|Department of Internal Medicine, Henry Ford Hospital, Detroit, MI, USA.
authors: Rehan M
authors: RM
authors: Hussain
authors: Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA.
authors: Alon
authors: A
authors: Harris
authors: Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA.
authors: Brent
authors: B
authors: Siesky
authors: Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA.
authors: Chi-Wah
authors: CW
authors: Yung
authors: Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA.|Department of Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.
authors: Rita
authors: R
authors: Ehrlich
authors: Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA.
authors: Ryan
authors: R
authors: Prall
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D052157:Aptamers, Nucleotide / Q000627:therapeutic use*; D001783:Blood Flow Velocity; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D006801:Humans; D056965:Injections, Intraocular; D007511:Ischemia / Q000188:drug therapy / Q000503:physiopathology*; D017078:Laser-Doppler Flowmetry; D008269:Macular Edema / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012161:Retinal Artery / Q000502:physiology*; D012170:Retinal Vein Occlusion / Q000188:drug therapy / Q000503:physiopathology; D018615:Ultrasonography, Doppler, Color; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D052157:Aptamers, Nucleotide; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib
references: Bonnin P, Pournaras JA, Lazrak Z et al. (2010): Ultrasound assessment of short-term ocular vascular effects of intravitreal injection of bevacizumab (Avastin) in neovascular age-related macular degeneration. Acta Ophthalmol 88: 641-645.
references: Cunningham ET Jr, Adamis AP, Altaweel M et al. (2005): A phase II randomized Double masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112: 1747-1757.
references: Gragoudas ES, Adamis AP, Cunningham ET Jr et al. (2004): Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816.
references: Papadopoulou DN, Mendrinos E, Mangioris G et al. (2009): Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. Ophthalmology 116: 1755-1761.
references: Wroblewski JJ, Wells JA 3rd & Gonzales CR (2010): Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion. Am J Ophthalmol 149: 147-154.